Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Proteomics International Laboratories Ltd. ( (AU:PIQ) ).
Proteomics International Laboratories Ltd announced the publication of a peer-reviewed study in the Internal Medicine Journal, demonstrating the clinical utility of their PromarkerD test in Australia. The study showed that PromarkerD significantly influences clinical decision-making by prompting earlier initiation of renoprotective therapies and reducing the use of nephrotoxic drugs among patients at risk of diabetic kidney disease. With 89% of surveyed physicians believing in the test’s potential to improve clinical outcomes, the findings support PromarkerD’s role in enhancing treatment strategies for the 1.5 million Australians with type 2 diabetes, potentially leading to better patient management and reduced healthcare costs.
The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.43 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
More about Proteomics International Laboratories Ltd.
Proteomics International Laboratories Ltd is a company operating in the biotechnology industry, focusing on the development of diagnostic tests. Their primary product, PromarkerD, is a blood test designed to predict the onset of diabetic kidney disease (DKD) in patients with type 2 diabetes, providing an early warning system to improve patient outcomes.
Average Trading Volume: 371,818
Technical Sentiment Signal: Hold
Current Market Cap: A$80.23M
Find detailed analytics on PIQ stock on TipRanks’ Stock Analysis page.